192 related articles for article (PubMed ID: 18263597)
1. Long-term experience of bosentan for treating ulcers and healed ulcers in systemic sclerosis patients.
García de la Peña-Lefebvre P; Rodríguez Rubio S; Valero Expósito M; Carmona L; Gámir Gámir ML; Beltrán Gutiérrez J; Díaz-Miguel C; Orte Martínez J; Zea Mendoza AC
Rheumatology (Oxford); 2008 Apr; 47(4):464-6. PubMed ID: 18263597
[TBL] [Abstract][Full Text] [Related]
2. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist.
Korn JH; Mayes M; Matucci Cerinic M; Rainisio M; Pope J; Hachulla E; Rich E; Carpentier P; Molitor J; Seibold JR; Hsu V; Guillevin L; Chatterjee S; Peter HH; Coppock J; Herrick A; Merkel PA; Simms R; Denton CP; Furst D; Nguyen N; Gaitonde M; Black C
Arthritis Rheum; 2004 Dec; 50(12):3985-93. PubMed ID: 15593188
[TBL] [Abstract][Full Text] [Related]
3. Bosentan in clinical practice for treating digital and other ischemic ulcers in Spanish patients with systemic sclerosis: IBER-DU cohort study.
Roman Ivorra JA; Simeon CP; Alegre Sancho JJ; Egurbide MV; Castillo MJ; Lloria X; Fonollosa V
J Rheumatol; 2011 Aug; 38(8):1631-5. PubMed ID: 21632679
[TBL] [Abstract][Full Text] [Related]
4. Effect of bosentan on skin fibrosis in patients with systemic sclerosis: a prospective, open-label, non-comparative trial.
Kuhn A; Haust M; Ruland V; Weber R; Verde P; Felder G; Ohmann C; Gensch K; Ruzicka T
Rheumatology (Oxford); 2010 Jul; 49(7):1336-45. PubMed ID: 20371505
[TBL] [Abstract][Full Text] [Related]
5. Bosentan for digital ulcers in patients with systemic sclerosis: a prospective 3-year followup study.
Tsifetaki N; Botzoris V; Alamanos Y; Argyriou E; Zioga A; Drosos AA
J Rheumatol; 2009 Jul; 36(7):1550-2. PubMed ID: 19567637
[No Abstract] [Full Text] [Related]
6. Bosentan as a rescue therapy in scleroderma refractory digital ulcers.
Chamaillard M; Heliot-Hosten I; Constans J; Taïeb A
Arch Dermatol; 2007 Jan; 143(1):125-6. PubMed ID: 17224564
[No Abstract] [Full Text] [Related]
7. [Bosentan for treatment of active digital ulcers in patients with systemic sclerosis].
Launay D; Diot E; Pasquier E; Mouthon L; Boullanger N; Fain O; Jego P; Carpentier P; Hatron PY; Hachulla E
Presse Med; 2006 Apr; 35(4 Pt 1):587-92. PubMed ID: 16614599
[TBL] [Abstract][Full Text] [Related]
8. Effects of bosentan on nondigital ulcers in patients with systemic sclerosis.
Taniguchi T; Asano Y; Hatano M; Tamaki Z; Tomita M; Kawashima T; Miyazaki M; Sumida H; Akamata K; Takahashi T; Ichimura Y; Toyama T; Sugita M; Noda S; Yao A; Kinugawa K; Sato S
Br J Dermatol; 2012 Feb; 166(2):417-21. PubMed ID: 21848685
[TBL] [Abstract][Full Text] [Related]
9. Effect of the dual endothelin receptor antagonist bosentan on Raynaud's phenomenon secondary to systemic sclerosis: a double-blind prospective, randomized, placebo-controlled pilot study.
Nguyen VA; Eisendle K; Gruber I; Hugl B; Reider D; Reider N
Rheumatology (Oxford); 2010 Mar; 49(3):583-7. PubMed ID: 20040526
[TBL] [Abstract][Full Text] [Related]
10. Safety and tolerability of bosentan for digital ulcers in Japanese patients with systemic sclerosis: Prospective, multicenter, open-label study.
Hamaguchi Y; Sumida T; Kawaguchi Y; Ihn H; Tanaka S; Asano Y; Motegi SI; Kuwana M; Endo H; Takehara K
J Dermatol; 2017 Jan; 44(1):13-17. PubMed ID: 27374274
[TBL] [Abstract][Full Text] [Related]
11. Successful treatment of systemic sclerosis-related digital ulcers and sarcoidosis with endothelin receptor antagonist (bosentan) therapy.
Tillon J; Hervé F; Chevallier D; Muir JF; Levesque H; Marie I
Br J Dermatol; 2006 May; 154(5):1000-2. PubMed ID: 16634913
[No Abstract] [Full Text] [Related]
12. Bosentan and sildenafil: successful treatment in a sclerodermic patient with refractory ulcers.
Catarsi E; Doveri M; Tavoni A
Reumatismo; 2013 May; 65(2):79-81. PubMed ID: 23877412
[TBL] [Abstract][Full Text] [Related]
13. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial.
Matucci-Cerinic M; Denton CP; Furst DE; Mayes MD; Hsu VM; Carpentier P; Wigley FM; Black CM; Fessler BJ; Merkel PA; Pope JE; Sweiss NJ; Doyle MK; Hellmich B; Medsger TA; Morganti A; Kramer F; Korn JH; Seibold JR
Ann Rheum Dis; 2011 Jan; 70(1):32-8. PubMed ID: 20805294
[TBL] [Abstract][Full Text] [Related]
14. Bosentan for digital ulcers in patients with systemic sclerosis.
Nagai Y; Hasegawa M; Hattori T; Okada E; Tago O; Ishikawa O
J Dermatol; 2012 Jan; 39(1):48-51. PubMed ID: 21955007
[TBL] [Abstract][Full Text] [Related]
15. [Digital ulcers in systemic sclerosis : A retrospective heath service study analysing treatment with bosentan and other vasoactive therapies].
Riemekasten G; Beissert S; Distler JH; Kreuter A; Müller-Ladner U
Z Rheumatol; 2017 Apr; 76(3):228-237. PubMed ID: 27535277
[TBL] [Abstract][Full Text] [Related]
16. Digital ulcers in scleroderma patients: A retrospective observational study.
De Cata A; Inglese M; Molinaro F; De Cosmo S; Rubino R; Bernal M; Mazzoccoli G
Int J Immunopathol Pharmacol; 2016 Jun; 29(2):180-7. PubMed ID: 26684622
[TBL] [Abstract][Full Text] [Related]
17. Blood flow in the hands of a predefined homogeneous systemic sclerosis population: the presence of digital ulcers and the improvement with bosentan.
Meijs J; Voskuyl AE; Bloemsaat-Minekus JP; Vonk MC
Rheumatology (Oxford); 2015 Feb; 54(2):262-9. PubMed ID: 25150178
[TBL] [Abstract][Full Text] [Related]
18. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers.
Abou-Raya A; Abou-Raya S; Helmii M
J Rheumatol; 2008 Sep; 35(9):1801-8. PubMed ID: 18709692
[TBL] [Abstract][Full Text] [Related]
19. Digital ulcers and outcomes assessment in scleroderma.
Matucci-Cerinic M; Seibold JR
Rheumatology (Oxford); 2008 Oct; 47 Suppl 5():v46-7. PubMed ID: 18784143
[TBL] [Abstract][Full Text] [Related]
20. Bosentan in systemic sclerosis.
Heresi GA; Minai OA
Drugs Today (Barc); 2008 Jun; 44(6):415-28. PubMed ID: 18596996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
